PPVC - Key Persons
Job Titles:
- LIFE SCIENCES Management Consultant
Bill is a LIFE SCIENCES Management Consultant with extensive operations experience. Particular expertise in Organizational Transformation as well as Supply Chain, Portfolio, and Resource Management. Skillfully leads and influences others in matrix-environment to achieve project plan objectives.
Job Titles:
- President and Founder of Pipeline Physics LLC
Dr. Gary Summers is President and Founder of Pipeline Physics LLC, a consulting boutique that provides research, education and consulting for project portfolio management (PPM) and the management of pharmaceutical pipelines.
Dr. Summers develops decisions methods that manage uncertainty well. These methods replace the predict-then-act approach of decision analysis and portfolio optimization with robust and flexible decision methods. In situations that are only partially understood, contain unknown-unknowns, and more generally, produce surprises, robust, flexible decision methods are best.
New decision theory is creating this field, and Dr. Summers is pioneering its application to PPM and Pharmaceutical pipelines. His research is producing:
A new Bayesian model of Pharmaceutical pipelines, which shows how upstream decisions affect downstream results, especially late-stage attrition.
Feedback for improving the management of Pharmaceutical pipelines. Metaphorically, it is evidence-based medicine for pipeline management.
Simulation technology for studying and teaching decision-making, teaming and PPM. This technology won a Best Paper Award from the Association of Business Simulation and Experiential Learning.
Robust methods and metrics for evaluating and selecting projects in phase-gate systems and Pharmaceutical pipelines.
Jianwei started his consulting career as an associate at McKinsey & Company where he worked with middle and upper management of major Pharmaceutical companies on planning and implementing strategies for achieving a superior competitive position. Highlights of McKinsey engagements include:
Conducted clinical operations benchmarking among leading global Pharmaceutical companies to improve clinical trial operations.
Facilitated the merger of two major global Pharmaceutical companies' animal health divisions; designed the commercial and R&D organizations of the merged division.
Identified licensing and acquisition targets for a major Pharmaceutical company; helped it to round its product portfolio and maintain annual revenue growth rate of 10%.
Identified and evaluate major trends that will impact Pharmaceutical industry valuation in the next decade and levers that Pharmaceutical companies can pull to unlock value.
Designed go-to-market strategy for a major CV medical device product.
Jianwei also has extensive experience in competitive intelligence and competitive strategies and directed global CI projects serving major Pharmaceutical companies:
Managed multi-national team to conduct competitive intelligence research and analysis, and assisted Pharmaceutical clients to plan R&D, BD&L, and commercial strategies based on competitive market landscape.
Responsible for equity research of a start-up hedge fund.
Lotte has accrued diverse expertise, spanning from drug discovery, clinical development, strategic planning to licensing/business development, during her 26-year tenure at Bristol-Myers Squibb Co.
She gained substantial drug development and life-cycle management skills as a Project Manager, coordinating and participating in a major, successful global regulatory filing. Earlier in her career, she conducted research in the cancer discovery area with special focus on drug resistance. She also managed drug metabolism & pharmacokinetics groups.
Throughout her career, she has been involved with diverse therapeutic areas, including: oncology, cardiovascular, metabolics, antiviral (HIV, HBV, HCV), immunology, neuroscience and dermatology.
Most recent position - Licensing Director, Bristol-Myers Squibb, where she led numerous technical due diligences and played key roles in some worldwide deals with biotech and major pharmaceutical companies. In addition, she implemented an in-house Competitive Intelligence network.